Novartis stock pre-market at EUR 125.01: minus 0.28 percent
Published on 10/05/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock was at EUR 125.01 pre-market at 8:12 a.m. CEST on October 5, 2026, according to Lang & Schwarz. The price was down EUR 0.35, or 0.28 percent, versus the Lang & Schwarz prior close of EUR 125.36 on October 2, 2026.
Novartis before the Xetra open
The Lang & Schwarz bid was EUR 124.52 and the ask was EUR 125.50. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
Positive European regulatory opinion
Novartis said in a September 18, 2026 press release that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for Cosentyx, or secukinumab, in polymyalgia rheumatica. If approved, the company said Cosentyx would be the first interleukin-17A inhibitor licensed in Europe for adults with the condition. Novartis described the opinion as a potential new treatment option for patients after steroid therapy.
